Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 1,865 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: First Treatment Period Clear all

Conditions: Cerebrovascular Accident
Interventions: TR intervention, In-home messaging device., Usual care; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 45 Years to 90 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 3
States / cities: Decatur, Georgia • Indianapolis, Indiana • Durham, North Carolina

Conditions: Interstitial Cystitis, Chronic Interstitial Cystitis, Bladder Pain Syndrome
Interventions: Desert Harvest Aloe Vera Capsules, Placebo Capsules; Drug · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Peripheral T Cell Lymphoma
Interventions: Nivolumab, Etoposide, Prednisolone, Oncovin, Cyclophosphamide, Hydroxydaunorubicin; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: Duarte, California • Aurora, Colorado • Philadelphia, Pennsylvania

Conditions: Multiple Myeloma
Interventions: Bortezomib, Lenalidomide, Dexamethasone; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Cancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck Cancer
Interventions: Atezolizumab, Tocilizumab, Tiragolumab; Biological
Lead sponsor: Alain Algazi; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Tobacco Use Disorder
Interventions: Ramelteon, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Premature Ventricular Beats
Interventions: Ranolazine; Drug
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Von Willebrand Disease
Interventions: Vonicog alfa, Antihemophilic Factor (Recombinant); Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: Up to 17 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 16
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Jacksonville, Florida + 12 more

Conditions: Breast Neoplasms, Musculoskeletal Pain
Interventions: Hypnosis, Attention Control; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Female only
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus, Type 1
Interventions: Insulin Lispro, regular human insulin, recombinant human hyaluronidase PH20, Insulin glargine; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 8
States / cities: Aurora, Colorado • Miami, Florida • Detroit, Michigan + 5 more

Conditions: Hypercholesterolemia
Interventions: Evolocumab, Standard of care; Biological · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 78
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 66 more

Conditions: Sepsis, Severe, Septic Shock
Interventions: Smoflipid; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: Scleritis
Interventions: Sirolimus; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists, Fluticasone furoate/umeclidinium/vilanterol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Waterbury, Connecticut • Charlotte, North Carolina • Layton, Utah

Conditions: Anxiety Disorders
Interventions: Structured games, Playgroup; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 48 Months to 71 Months
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Ann Arbor, Michigan • East Lansing, Michigan • New York, New York

Conditions: Body Dysmorphic Disorder, Obsessive-compulsive Disorder
Interventions: Oxytocin, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Laryngeal Squamous Cell Carcinoma
Interventions: Cisplatin, Epinephrine injection, Laryngeal Biopsy, Endoscopic Surgery; Drug · Procedure
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 2,604 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Opioid Tapering
Interventions: Treatment as Usual (TAU), Telephonic Support (TS) Providers, DOTS Intervention; Other
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: SCN8A Developmental and Epileptic Encephalopathy Syndrome
Interventions: NBI-921352, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 2 Years to 21 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: San Francisco, California • Washington D.C., District of Columbia • Rochester, New York + 1 more

Conditions: Asthma
Interventions: Breathing exercise; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Sarcoma, Alveolar Soft Part
Interventions: Cediranib, Sunitinib, Prochlorperazine, Promethazine, Benzodiazepine, Filgrastim, Sargramostim, Lomotil, Loperamide, Vitamin B6, Aquaphor, Acetaminophen, Levothyroxine, Warfarin; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years to 120 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Symptomatic Neurogenic Orthostatic Hypotension
Interventions: Droxidopa capsules, Placebo capsules; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years and older
Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 168
States / cities: Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 103 more

Conditions: Carcinoma, Hepatocellular
Interventions: Lenvatinib; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Pasadena, California • Gainesville, Florida • Louisville, Kentucky + 1 more

Search by objective public record fields.

Home-based Telehealth Stroke Care: A Randomized Trial for Veterans

Safety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial Cystitis

Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas

Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma

Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

Effect of Ramelteon on Smoking Abstinence

Study to Reduce Symptoms of Premature Beats With Ranolazine

A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

Hypnosis to Reduce Aromatase Inhibitor Pain and Improve Adherence

Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus

Open Label Study of Long Term Evaluation Against LDL-C Trial

LIPIDS-P Trial Phase I/II Trial

Sirolimus Injections for Autoimmune Scleritis

Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study

Kidpower Camp - Structured Games or Playgroup

Oxytocin Administration in BDD and OCD

Intralesional Chemotherapy (IC): Cisplatin + Epinephrine

A Real-world Study Comparing the Effectiveness of Ofatumumab and Ocrelizumab Treatment in Multiple Sclerosis Patients

Opioid Tapering After Hospital Discharge: Testing an Intervention to Improve Post-operative Opioid Prescribing

Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)

Breathing Exercises for Asthma

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension

Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)